3 results
Approved WMOCompleted
Primary Objective:To demonstrate that CHF 1535 twice daily is superior to Formoterol twice daily in terms of COPD exacerbations rate during 48 weeks of treatment and in terms of pulmonary function (change in pre-dose morning FEV1 from baseline to 12…
Not approvedWill not start
This study investigates the safety and tolerability of deferoxamine use in patients with aneurysma subarachnoid hemorrhage.
Approved WMORecruiting
This study investigates the effectivity and the safety of deferoxamine use in patients with aneurysma subarachnoidhemorrhage.